Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Gritstone OncologyJounce TherapeuticsOyster Point PharmaSolid BiosciencesMeiraGTx
SymbolNASDAQ:GRTSNASDAQ:JNCENASDAQ:OYSTNASDAQ:SLDBNASDAQ:MGTX
Price Information
Current Price$8.57$9.77$21.19$5.30$13.70
52 Week RangeHoldBuyBuyBuyBuy
MarketRank™
Overall Score1.61.61.01.81.4
Analysis Score3.23.30.03.43.5
Community Score2.72.72.32.62.9
Dividend Score0.00.00.00.00.0
Ownership Score1.71.72.52.50.8
Earnings & Valuation Score0.60.60.00.60.0
Analyst Ratings
Consensus RecommendationHoldBuyBuyBuyBuy
Consensus Price Target$22.33$15.50N/A$12.40$33.00
% Upside from Price Target160.60% upside58.65% upsideN/A133.96% upside140.88% upside
Trade Information
Market Cap$433.23 million$419.89 million$544.11 million$529.05 million$601.99 million
Beta1.21.34-0.381.11.33
Average Volume3,135,653537,49486,4151,678,286114,048
Sales & Book Value
Annual Revenue$4.36 million$147.87 millionN/AN/A$13.29 million
Price / Sales96.223.00N/AN/A45.63
CashflowN/A$2.38 per shareN/AN/AN/A
Price / CashN/A4.11N/AN/AN/A
Book Value$3.75 per share$5.25 per share$6.43 per share$1.74 per share$5.22 per share
Price / Book2.291.86N/AN/A2.62
Profitability
Net Income$-94,430,000.00$56.82 million$-45,710,000.00$-117,220,000.00$-54,750,000.00
EPS($2.81)$1.66($9.97)($2.91)($1.65)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-2,962.52%N/AN/AN/A-283.20%
Return on Equity (ROE)-101.31%-72.91%-39.61%-194.22%-29.14%
Return on Assets (ROA)-68.78%-59.68%-37.68%-140.40%-17.49%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.29%N/AN/A0.03%0.10%
Current Ratio3.35%6.60%22.78%1.84%4.67%
Quick Ratio3.35%6.60%22.78%1.84%4.67%
Ownership Information
Institutional Ownership Percentage58.98%60.48%70.16%42.73%56.40%
Insider Ownership Percentage38.00%43.96%36.90%31.20%16.50%
Miscellaneous
Employees16912862121219
Shares Outstanding48.95 million45.39 million25.91 million106.88 million44.26 million
Next Earnings Date5/6/2021 (Estimated)5/5/2021 (Estimated)5/10/2021 (Estimated)5/6/2021 (Estimated)5/6/2021 (Estimated)
OptionableNot OptionableOptionableNot OptionableOptionableNot Optionable
SourceHeadline
Parkinson s disease Market Will Reflect Significant Growth Prospects During the Study Period [2018-2030], Anticipates DelveInsight - PRNewswireParkinson 's disease Market Will Reflect Significant Growth Prospects During the Study Period [2018-2030], Anticipates DelveInsight - PRNewswire
prnewswire.com - April 14 at 2:05 PM
MeiraGTx (NASDAQ:MGTX) versus TRACON Pharmaceuticals (NASDAQ:TCON) Head to Head ReviewMeiraGTx (NASDAQ:MGTX) versus TRACON Pharmaceuticals (NASDAQ:TCON) Head to Head Review
americanbankingnews.com - April 11 at 8:14 AM
Retinal Biologics Market Revenue Worth $X.XX Billion By 2028: F. Hoffmann-La Roche, Regeneron Pharmaceuticals Inc., AbbVie Inc., MeiraGTx Limited, Oxurion NV, Novartis, Merck & Co., Inc., etc. - Jumbo NewsRetinal Biologics Market Revenue Worth $X.XX Billion By 2028: F. Hoffmann-La Roche, Regeneron Pharmaceuticals Inc., AbbVie Inc., MeiraGTx Limited, Oxurion NV, Novartis, Merck & Co., Inc., etc. - Jumbo News
jumbonews.co.uk - April 11 at 7:43 AM
Retinal therapeutic clinical trials address disease at core - Ophthalmology TimesRetinal therapeutic clinical trials address disease at core - Ophthalmology Times
ophthalmologytimes.com - April 10 at 5:26 AM
Retinal therapeutic clinical trials address disease at core - Ophthalmology TimesRetinal therapeutic clinical trials address disease at core - Ophthalmology Times
ophthalmologytimes.com - April 10 at 5:26 AM
Head-To-Head Analysis: Genfit (NASDAQ:GNFT) & MeiraGTx (NASDAQ:MGTX)Head-To-Head Analysis: Genfit (NASDAQ:GNFT) & MeiraGTx (NASDAQ:MGTX)
americanbankingnews.com - April 4 at 6:10 AM
MeiraGTx (NASDAQ:MGTX) Shares Gap Up to $14.15MeiraGTx (NASDAQ:MGTX) Shares Gap Up to $14.15
americanbankingnews.com - March 26 at 11:05 AM
MeiraGTx (NASDAQ:MGTX) Shares Gap Down to $15.93MeiraGTx (NASDAQ:MGTX) Shares Gap Down to $15.93
americanbankingnews.com - March 24 at 11:54 AM
MEIRAGTX HOLDINGS PLC MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - marketscreener.comMEIRAGTX HOLDINGS PLC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - marketscreener.com
marketscreener.com - March 12 at 9:34 PM
Form 10-K MeiraGTx Holdings plc For: Dec 31 - StreetInsider.comForm 10-K MeiraGTx Holdings plc For: Dec 31 - StreetInsider.com
streetinsider.com - March 11 at 3:06 PM
MeiraGTx Reports Fourth Quarter and Full Year 2020 Financial and Operational Results - Yahoo FinanceMeiraGTx Reports Fourth Quarter and Full Year 2020 Financial and Operational Results - Yahoo Finance
finance.yahoo.com - March 11 at 9:40 AM
MeiraGTx Reports Fourth Quarter and Full Year 2020 Financial and Operational ResultsMeiraGTx Reports Fourth Quarter and Full Year 2020 Financial and Operational Results
finance.yahoo.com - March 11 at 9:40 AM
Kadmon Provides Business Update and Reports Fourth Quarter 2020 Financial Results - StreetInsider.comKadmon Provides Business Update and Reports Fourth Quarter 2020 Financial Results - StreetInsider.com
streetinsider.com - March 4 at 8:19 PM
MeiraGTx to Present at the 2021 Barclays Global Healthcare ConferenceMeiraGTx to Present at the 2021 Barclays Global Healthcare Conference
finance.yahoo.com - March 4 at 1:00 PM
Earnings Preview: MeiraGTx Holdings PLC (MGTX) Q4 Earnings Expected to Decline - NasdaqEarnings Preview: MeiraGTx Holdings PLC (MGTX) Q4 Earnings Expected to Decline - Nasdaq
nasdaq.com - March 3 at 3:23 PM
Earnings Preview: MeiraGTx Holdings PLC (MGTX) Q4 Earnings Expected to DeclineEarnings Preview: MeiraGTx Holdings PLC (MGTX) Q4 Earnings Expected to Decline
finance.yahoo.com - March 3 at 3:23 PM
Analysts Offer Insights on Healthcare Companies: Meiragtx Holdings (MGTX) and Anavex Life Sciences (AVXL) - Smarter AnalystAnalysts Offer Insights on Healthcare Companies: Meiragtx Holdings (MGTX) and Anavex Life Sciences (AVXL) - Smarter Analyst
smarteranalyst.com - February 17 at 8:16 AM
Applied Genetic Technologies: Leader Among Larger Peers In Gene Therapies For Certain Eye Diseases - Seeking AlphaApplied Genetic Technologies: Leader Among Larger Peers In Gene Therapies For Certain Eye Diseases - Seeking Alpha
seekingalpha.com - February 16 at 12:00 PM
FDA grants genetic treatment fast-track status - AOPFDA grants genetic treatment fast-track status - AOP
aop.org.uk - February 12 at 11:45 AM
Is MeiraGTx Holdings plc (NASDAQ:MGTX) Popular Amongst Insiders?Is MeiraGTx Holdings plc (NASDAQ:MGTX) Popular Amongst Insiders?
finance.yahoo.com - February 8 at 1:21 PM
Transcript: Optometry Times® news summary 2/7/2021 - Optometry TimesTranscript: Optometry Times® news summary 2/7/2021 - Optometry Times
optometrytimes.com - February 5 at 8:23 PM
With $100M MeiraGTx Deal, J&J Signals Bigger Move Into Gene TherapyWith $100M MeiraGTx Deal, J&J Signals Bigger Move Into Gene Therapy
xconomy.com - February 1 at 8:15 PM
FDA grants fast track designation to gene therapy candidate for achromatopsia - HealioFDA grants fast track designation to gene therapy candidate for achromatopsia - Healio
healio.com - January 27 at 6:51 PM
Our First Look At MeiraGTx Holdings - Seeking AlphaOur First Look At MeiraGTx Holdings - Seeking Alpha
seekingalpha.com - January 27 at 6:51 PM
News Brief: J&J Could Supply US with 100 Million COVID-19 Vaccine Doses and More - BioSpaceNews Brief: J&J Could Supply US with 100 Million COVID-19 Vaccine Doses and More - BioSpace
biospace.com - January 27 at 1:50 PM
DateCompanyBrokerageAction
1/21/2021Gritstone OncologyBTIG ResearchBoost Price Target
1/20/2021Gritstone OncologyHC WainwrightBoost Price Target
1/20/2021Gritstone OncologyRobert W. BairdDowngrade
1/15/2020Gritstone OncologyCowenReiterated Rating
3/27/2019Gritstone OncologyBerenberg BankInitiated Coverage
3/14/2019Gritstone OncologyRaymond JamesInitiated Coverage
10/23/2018Gritstone OncologyBarclaysInitiated Coverage
10/23/2018Gritstone OncologyThe Goldman Sachs GroupInitiated Coverage
3/22/2021Jounce TherapeuticsPiper SandlerInitiated Coverage
11/10/2020Jounce TherapeuticsRoth CapitalLower Price Target
8/21/2020Jounce TherapeuticsJPMorgan Chase & Co.Reiterated Rating
10/27/2020Oyster Point PharmaLifesci CapitalReiterated Rating
11/25/2019Oyster Point PharmaPiper Jaffray CompaniesInitiated Coverage
3/22/2021Solid BiosciencesSVB LeerinkUpgrade
3/22/2021Solid BiosciencesCredit Suisse GroupBoost Price Target
3/22/2021Solid BiosciencesChardan CapitalBoost Price Target
5/21/2020Solid BiosciencesNomuraReiterated Rating
12/18/2019Solid BiosciencesNomura SecuritiesBoost Price Target
10/11/2019Solid BiosciencesEvercore ISIInitiated Coverage
8/29/2019Solid BiosciencesCitigroupDowngrade
10/22/2020MeiraGTxRoyal Bank of CanadaInitiated Coverage
9/15/2020MeiraGTxBank of AmericaInitiated Coverage
(Data available from 4/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.